Enter your terms above and click the 'Search' button.

Showing articles 0 to 2 of 2 Filter Applied: cost (Click to remove) Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021 Second Drug Okayed for Rare Central Nervous System Disease JAMA 324:224, Jaklevic, M.C., 2020 Showing articles 0 to 2 of 2